Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Vir Biotechnology, Inc. reported revenue of $69M, down 7.6% year over year. Operating margin was -699.2% and net margin -638.9%, on a free-cash-flow margin of -578.5% with capital expenditure at 7.0% of revenue. Every figure is computed directly from VIR's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $69M | -699.2% | -638.9% |
| FY2024 | $74M | -791.3% | -703.4% |
| FY2023 | $86M | -794.0% | -713.7% |
| FY2022 | $1.62B | 51.6% | 31.9% |
| FY2021 | $1.10B | 38.4% | 48.3% |
How does VIR compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.